Dendreon researchers have presented data from the PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 trial suggesting that sipuleucel-T (Provenge) induces durable responses that can be maintained following an immune boost. These early data from the PROTECT trial were presented Sunday at the annual meeting of the American Association for Cancer Research [...]
Filed under: Drugs in development, Management, Treatment | Tagged: androgen-dependent, Provenge, sipleucel-T | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
